SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Merck

72

Merck

MRK

Revenue for the 165-year-old drug maker slid 6.5% in 2015 largely due to currency fluctuations and divestitures. In the U.S., sales grew on the strong performance of its diabetes and cancer medications and as a result of its $8.3 billion acquisition of antibiotic maker Cubist Pharmaceuticals. The company also pressed ahead with restructuring efforts–it shed 2,000 jobs in 2015–and kept pace in the industry immunotherapy race, with the widening range of approved uses for Keytruda, Merck’s breakthrough immuno-oncology drug.

CEO

Kenneth C. Frazier

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Kenilworth, NJ

Years on Fortune 500 List

22

Employees

68,000

Merck is also featured in these fortune lists
Key Financials (last fiscal year)
$ millions% change
Revenues ($M)$39,498-6.5%
Profits ($M)$4,442-62.7%
Assets ($M)$101,779
Total Stockholder Equity ($M)$44,676
Market Value — as of March 31, 2016 ($M)$146,839
Profit Ratios
Profit as % of Revenues11.2%
Profits as % of Assets4.4%
Profits as % of Stockholder Equity9.9%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)1.56
EPS % Change (from 2014)-61.7%
EPS % Change (5 year annual rate)41.0%
EPS % Change (10 year annual rate)-2.9%
Total Return
Total Return to Investors (2015)-4.0%
Total Return to Investors (5 year, annualized)12.0%
Total Return to Investors (10 year, annualized)9.4%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Merck

Prepare for the Digital Health Revolution

Here are 21 companies using technology to reinvent the business of medicine.

Read More →
Trump Is Slashing FDA Rules. Why Isn’t Big Pharma Excited?

The industry is wary of the coming FDA streamlining.

Read More →
Pharma Executives Aren't Excited About Trump's Plans to Ease FDA Regulation

They say a robust review process is needed to convince doctors and insurers new drugs have value.

Read More →